Study: Phorcides for Myopia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Vance Thompson Vision, Sioux Falls, SD
Myopia+1 More
Contoura with Phorcides - Procedure
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

Eligible Conditions

  • Myopia
  • Astigmatism

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 3 months post-op

3 months post-op
Corrected Distance Visual Acuity
Low Contrast Visual Acuity
Post-OP BCVA
Post-Op UDVA
Pre-op and post-op visual acuity
Residual Refractive Error

Trial Safety

Trial Design

2 Treatment Groups

Control: Wavefront Optimized
1 of 2
Study: Phorcides
1 of 2
Active Control
Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: Study: Phorcides · No Placebo Group · N/A

Study: Phorcides
Procedure
Experimental Group · 1 Intervention: Contoura with Phorcides · Intervention Types: Procedure
Control: Wavefront Optimized
Device
ActiveComparator Group · 1 Intervention: WaveLight Wavefront Optimized · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months post-op
Closest Location: Vance Thompson Vision · Sioux Falls, SD
2013First Recorded Clinical Trial
5 TrialsResearching Myopia
32 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Candidates for Contoura with Phorcides (Myopic, astigmatism <3.
Both eyes targeted for plano.
The corneal pachymetry 490um or above.
You are willing and able to comprehend informed consent and complete 1 month post-op visit.
You have 20/20 or better vision in each eye based on Investigator's medical opinion.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.